Advertisement

Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Twenty patients (18 men, 2 women) with non-insulin dependent diabetes mellitus (NIDDM) were randomized to receive either gemfibrozil 1200 mg daily or placebo for 3 months in a double-blind study. The effect of gemfibrozil on plasma HDL subfraction distribution was studied with sequential and density gradient ultracentrifugation and in gradient gel electrophoresis. The concentrations of apo A-I, apo A-II, Lp A-I and Lp A-LA-11 particles were measured. Postheparin plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activities and plasma cholesteryl ester transfer protein (CETP) activities were also determined. Gemfibrozil increased the concentration of HDL cholesterol (P < 0.01), which was due to the rise of HDL3 cholesterol (+16%), while in the placebo group these values remained unchanged. Gemfibrozil increased the concentrations of apo A-I(+12.6%, NS), apo A-II (+28.2%, P < 0.01) and Lp A-I:A-II particles (+21.6%, P < 0.06) but there were no changes in the placebo group. Neither gemfibrozil nor placebo had any effect on the concentration of Lp A-I particles. As determined by density-gradient ultracentrifugation, gemfibrozil increased the concentration of cholesterol in the most dense HDL fractions (mean density 1.193 g/ml, +22%, P < 0.05 and mean density 1.158 g/ml, +19.3%, P < 0.05). In gradient gel electrophoresis, the gemfibrozil-induced elevations of the cholesterol and protein were most pronounced in the HDL3,, (8.8−8.2 nm) region. Gemfibrozil increased LPL and HL activities by 14.7% (P < 0.05) and by 18.8% (P < 0.01), respectively, while in the placebo group LPL and HL activities remained unchanged. Plasma CETP activity was also increased during gemfibrozil treatment while in the placebo group it remained unchanged. We conclude that gemfibrozil causes multiple changes in plasma HDL metabolism. The gemfibrozil-induced elevation of HDL3 and dense HDL subpopulations may reflect the concerted action of LPL, HL and CETP on plasma HDL metabolism.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Taskinen M.R.
        Hyperlipidemia in diabetes.
        Baillière's Clin End. Metab. 1990; 4: 743
        • Pyörälä K.
        • Laakso M.
        • Uusitupa M.
        Diabetes and atherosclerosis: an epidemiologic review.
        Diabetes/Metab. Rev. 1987; 3: 463
        • Gordon D.J.
        • Rifkind B.M.
        High density lipoproteins — the clinical implications of recent studies.
        N. Eng. J. Med. 1989; 321: 1311
        • Gordon D.J.
        • Knoke J.
        • Probstfield J.L.
        • Superko R.
        • Tyrolel H.A.
        High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial.
        Circulation. 1986; 74: 1217
        • Manninen V.
        • Elo M.O.
        • Frick M.H.
        Lipid alterations in the incidence of coronary heart disease in the Helsinki Heart Study.
        J. Am. Med. Assoc. 1988; 260: 641
        • Patsch J.R.
        • Gotto A.M.
        Metabolism of high density lipoproteins.
        in: Gotto Jr., A.M. Plasma Lipoproteins. Elsevier, Amsterdam1987: 221
        • Shepherd J.
        • Packard C.J.
        • Gotto Jr., A.M.
        • Taunton O.D.
        A comparison of two methods to investigate the metabolism of human apolipoprotein A-I and A-II.
        J. Lipid Res. 1978; 19: 656
        • Nikkilä E.A.
        • Kuusi T.
        • Taskinen M.R.
        Role of lipoprotein lipase and hepatic endothelial lipase in the metabolism of high-density lipoproteins: a novel concept on cholesterol transport in HDL cycle.
        in: Carlson L.A. Pernow B. Metabolic Risk Factors in Ischemic Cardiovascular Disease. Raven Press, New York1982: 205
        • Tall A.R.
        Plasma high density lipoproteins. Metabolism and relation to atherogenesis.
        J. Clin. Invest. 1990; 86: 379
        • Grundy S.M.
        • Vega G.L.
        Fibric acids: Effects on lipids and lipoprotein metabolism.
        J. Am. Med. Assoc. 1987; 83: 9
        • Taskinen M.R.
        • Nikkilä E.A.
        Lipolytic enzymes and HDL: Influence of drugs and hormones.
        in: Paoletti R. Drugs Affecting Lipid Metabolism. Springer-Verlag, Berlin1987: 231
        • Chan M.K.
        Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high density lipoprotein subfractions.
        Metabolism. 1989; 38: 939
        • Vega G.L.
        • Grundy S.M.
        Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia.
        J. Am. Med. Assoc. 1989; 262: 3148
        • Saku K.
        • Gartside P.S.
        • Hynd B.A.
        • Kashyap M.L.
        Mechanism of action of gemfibrozil on lipoprotein metabolism.
        J. Clin. Invest. 1985; 75: 1702
        • Bhatnagar D.
        • Durrington P.N.
        • Mackness M.I.
        • Arrol S.
        • Winocour P.H.
        • Prais H.
        Effect of treatment of hypertriglyceridemia with gemfibrozil on serum lipopro teins and the transfer of cholesteryl esters from highdensity lipoprotein to low density lipoproteins.
        Atherosclerosis. 1992; 92: 49
        • Garg A.
        • Grundy S.M.
        Management of dyslipidemia in NIDDM.
        Diabetes Care. 1990; 13: 153
        • Vuorinen-Markkola H.
        • Yki-Järvinen H.
        • Taskinen M.R.
        Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic action of insulin in non-insulin-dependent diabetic patients.
        Diabetologia. 1993; 36: 161
        • Taskinen M.R.
        • Kuusi T.
        • Helve E.
        • Nikkilä E.A.
        • Yki-Järvinen H.
        Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes.
        Arteriosclerosis. 1988; 8: 168
        • Groot P.H.E.
        • Scheek L.M.
        • Havekes L.
        • van Noort W.L.
        • van't Hooft F.M.
        A one-step separation of human serum high density lipoproteins 2 and 3 by rate zonal ultracentrifugation in a swinging bucket rotor.
        J. Lipid Res. 1982; 23: 1342
        • Nichols A.N.
        • Krauss R.M.
        • Musliner T.A.
        Nondenaturing polyacrylamide gradient gel electrophoresis.
        Methods Enzymol. 1986; 128: 417
        • Verdery R.
        • Benham D.
        • Baldwin H.
        • Goldberg A.
        • Nichols A.
        Measurement of normative HDL subfraction cholesterol levels by Gaussian summation analysis of gradient gels.
        J. Lipid Res. 1989; 30: 1085
        • Huttunen J.K.
        • Ehnholm C.
        • Kinnunen P.J.
        • Nikkilä E.A.
        An immunochemical method for selective measurement of two triglyceride lipases in human postheparin plasma.
        Clin. Chim. Acta. 1975; 63: 335
        • Havel R.J.
        • Eder H.A.
        • Brigdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J. Clin. Invest. 1955; 34: 1345
        • Morton R.E.
        • Zilversmit D.B.
        A plasma inhibitor of triglyceride and cholesteryl ester transfer activities.
        J. Biol. Chem. 1981; 256: 11992
        • Kelley J.L.
        • Kruski A.W.
        Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor.
        Methods Enzymol. 1986; 128: 170
        • Groener J.E.M.
        • Pelton R.W.
        • Kostner G.M.
        Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma.
        Clin. Chem. 1986; 32: 283
        • Barter P.J.
        • Jones M.E.
        Rate of exchange of esterified cholesterol between human plasma low and high density lipoproteins.
        Atherosclerosis. 1982; 34: 67
        • Parra H.J.
        • Mezdour H.
        • Ghalim N.
        • Bard J.M.
        • Fruchart J.C.
        Differential electroimmunoassay of human Lp A-I lipoprotein particles on ready-to-use plates.
        Clin. Chem. 1990; 36: 1431
        • Wahlefeld A.W.
        Triglyceride determination after enzymatic hydrolysis.
        in: Bergmeyer H.V. Methods of Enzymatic Analysis. 2nd Edn. Academic Press, New York1974: 1831
        • Welch S.G.
        • Boucher D.J.
        A rapid micro-scale method for the measurement of haemoglobin AI(a+b+c).
        Diabetologia. 1978; 14: 209
        • Lahdenperä S.
        • Tilly-Kiesi M.
        • Vuorinen-Markkola H.
        • Kuusi T.
        • Taskinen M.R.
        Effects of gemfibrozil on low density lipoprotein particle size, density distribution and composition in patients with type 2 diabetes mellitus.
        Diabetes Care. 1993; 16: 584
        • Taskinen M.R.
        • Kuusi T.
        Enzymes involved in triglyceride hydrolysis.
        Baillière's Clin. Endocr. Metab. 1987; 1: 639
        • Sorisky A.
        • Ooi T.C.
        • Simo I.E.
        • et al.
        Change in composition of high-density lipoprotein during gemfibrozil therapy.
        Atherosclerosis. 1987; 67: 181
        • Mänttäri M.
        • Koskinen P.
        • Manninen V.
        • Huttunen J.K.
        • Frick M.H.
        • Nikkila E.A.
        Effect of gemfibrozil on the concentration and composition of serum lipoproteins.
        Atherosclerosis. 1990; 81: 11
        • Barter P.J.
        Plasma factors which transform high density lipoproteins.
        in: Carlson L.A. Disorders of HDL. Smith-Gordon, London1990: 31
        • Eisenberg S.
        • Gavish D.
        • Oschry Y.
        • Fainaru M.
        • Deckelbaum R.J.
        Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. Rever sal towards normal with bezafibrate treatment.
        J. Clin. Invest. 1984; 74: 470
        • Goldberg I.J.
        • Blaner W.S.
        • Vanni T.M.
        • Moukides M.
        • Ramakrishnan R.
        Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipaseinhibited monkeys.
        J. Clin. Invest. 1990; 86: 463
        • Brinton E.A.
        • Eisenberg S.
        • Breslow J.L.
        Increased apo A-I and apo A-11 fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia.
        J. Clin. Invest. 1991; 87: 536
        • Agellon L.B.
        • Walsh A.
        • Hayek T.
        • et al.
        Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice.
        J. Biol. Chem. 1991; 266: 10796
        • Inazrú A.
        • Brown M.L.
        • Hesler C.B.
        • et al.
        Increased high density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.
        N. Engl. J. Med. 1990; 323: 1234
        • Morton R.E.
        Binding of plasma-derived lipid transfer protein to lipoprotein substrates. The role of binding in the lipid transfer process.
        J. Biol. Chem. 1985; 260: 12593
        • Tilly-Kiesi M.
        • Tikkanen M.
        Low density lipoprotein density and composition in hypercholesterolemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
        J. Int. Med. 1991; 229: 427
        • Bard J.M.
        • Parra H.J.
        • Luc G.
        • et al.
        Lipoprotein particle analysis comparing simvastatin and fenofibrate.
        Atherosclerosis. 1991; 91: 529
        • Atmeh R.F.
        • Shepherd J.
        • Packard C.J.
        Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy.
        Biochim. Biophys. Acta. 1983; 751: 175
        • James R.W.
        • Pometta D.
        Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations.
        Atherosclerosis. 1990; 83: 35
        • Stampfer M.J.
        • Sacks F.M.
        • Salvini S.
        • Willett W.C.
        • Hennekens C.H.
        A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
        N. Engl. J. Med. 1991; 325: 373
        • Miller N.E.
        Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis.
        Am. Heart J. 1987; 113: 589
        • Barbaras R.
        • Puchois P.
        • Fruchart J.C.
        • Ailhaud G.
        Cholesterol efflux from cultured adipose cells is mediated by Lp A-1-particles but not by Lp A-LA-11-particles.
        Biochem. Biophys. Res. Commun. 1987; 142: 63
        • Barkia A.
        • Puchois P.
        • Ghalim N.
        • Torpier G.
        • Barbaras R.
        • Ailhaud G.
        • Fruchart J.C.
        Differential role of apolipoprotein AI-containing particles in choles terol efflux from adipose cells.
        Atherosclerosis. 1991; 87: 135
        • Puchois P.
        • Kandoussi A.
        • Fievet P.
        • et al.
        Apolipoprotein A-1 containing lipoproteins in coronary artery disease.
        Atherosclerosis. 1987; 68: 35
        • Johnson W.J.
        • Kilsdonk P.C.
        • van Tol A.
        • Phillips M.C.
        • Rothblat G.H.
        Cholesterol efflux from cells to immunopurified subtractions of human high density lipo protein: LP-AI and LP-AI/All.
        J. Lipid Res. 1991; 32: 1993
        • Coste-Burel M.
        • Mainard F.
        • Chivot L.
        • Auget J.L.
        • Madec Y.
        Study of lipoprotein particles Lp A-1 and Lp A-LA-II in patients before coronary bypass surgery.
        Clin. Chem. 1990; 36: 1889